Tolerance and pharmacokinetic interactions of rifabutin and azithromycin
R Hafner, J Bethel, H C Standiford, S Follansbee, D L Cohn, R E Polk, L Mole, R Raasch, P Kumar, D Mushatt, G Drusano, DATRI 001B Study Group, R Hafner, J Bethel, H C Standiford, S Follansbee, D L Cohn, R E Polk, L Mole, R Raasch, P Kumar, D Mushatt, G Drusano, DATRI 001B Study Group
Abstract
This multicenter study evaluated the tolerance and potential pharmacokinetic interactions between azithromycin and rifabutin in volunteers with or without human immunodeficiency virus infection. Daily dosing with the combination of azithromycin and rifabutin was poorly tolerated, primarily because of gastrointestinal symptoms and neutropenia. No significant pharmacokinetic interactions were found between these drugs.
Figures
Changes in the AUC0–24 of azithromycin (A), rifabutin (B), and 25-O-descetyl-rifabutin (C) for individual subjects between days 14 and 42.
Source: PubMed